Prasugrel is contraindicated in which of the following patient populations due to an increased risk of intracranial hemorrhage?
Show answer and explanation
Correct answer: Patients with prior stroke or TIA history
In clinical trials, Prasugrel was associated with a significant increase in major bleeding, including fatal intracranial hemorrhage, in patients with a prior history of stroke or TIA. Therefore, its use is strictly contraindicated in these individuals.
Keep practicing
More Antiplatelet Drugs questions
- Vorapaxar is a newer antiplatelet drug that targets which specific receptor?
- Which side effect is uniquely associated with Ticagrelor therapy and may lead to drug discontinuation?
- What is the rationale for using 'Dual Antiplatelet Therapy' (DAPT) in patients following coronary stent placement?
- Which of the following agents is a synthetic heptapeptide that reversibly inhibits the Glycoprotein IIb/IIIa receptor?
- How long before an elective surgery should Aspirin typically be discontinued to allow for the restoration of normal platelet function?
- Cilostazol is primarily indicated for the treatment of which condition?